{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:06Z","timestamp":1767485766113,"version":"3.48.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has transformed diffuse large B-cell lymphoma (DLBCL) treatment, but data in diverse urban populations remain limited. We report outcomes from a comprehensive cancer center in the Bronx.\u00a0Montefiore Health System treated 79 DLBCL patients with CAR-T from March 2018 to July 2024. Demographics, comorbidities, socioeconomic factors, and acute complications, including immune effector cell neurotoxicity syndrome (ICANS), cytokine release syndrome (CRS), cardiotoxicity, and pulmonary events, were tabulated. Kaplan-Meier survival analysis was performed up to five years. Multivariate adjusted hazard ratios (aHR) were calculated for remission and 3-year mortality.\u00a0CAR-T achieved complete remissions in 50.6%, partial remission in 16.5%, and progression in 22.8%. Cumulative mortality was 10.1% during treatment and 34.2% by five years. Complete remission reduced 3-year mortality (aHR 0.13; 95% CI 0.04\u20130.43). Complications included CRS (76.0%), ICANS (49.4%), neutropenic fever (58.2%), and sepsis (19.0%). ICANS correlated with CRS, ICU stay, and sepsis. Socioeconomic status was not linked to mortality, but comorbidities increased risk.\u00a0CAR-T complete remission is an independent predictor of reduced mortality. High rates of complications, particularly CRS and ICAN, reinforce the need for vigilant monitoring and management strategies to enhance long-term outcomes.<\/jats:p>","DOI":"10.1007\/s00277-025-06727-x","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:22:41Z","timestamp":1763014961000},"page":"6359-6371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes of CAR-T therapy from the Montefiore health system in the Bronx"],"prefix":"10.1007","volume":"104","author":[{"given":"Sonya","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiman","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Vichare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim Q.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"4","key":"6727_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388\u2013398","journal-title":"Cancer Discov"},{"key":"6727_CR2","doi-asserted-by":"crossref","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: What Is Next? Cancers (Basel) 15(3)","DOI":"10.3390\/cancers15030663"},{"issue":"6","key":"6727_CR3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","volume":"20","author":"CK Chou","year":"2020","unstructured":"Chou CK, Turtle CJ (2020) Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther 20(6):653\u2013664","journal-title":"Expert Opin Biol Ther"},{"issue":"35","key":"6727_CR4","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39(35):3978\u20133992","journal-title":"J Clin Oncol"},{"issue":"2","key":"6727_CR5","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ et al (2017) Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45(2):e124\u2013e31","journal-title":"Crit Care Med"},{"issue":"5","key":"6727_CR6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 146(5):940\u2013948","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"6727_CR7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jpainsymman.2024.11.002","volume":"69","author":"W Sun","year":"2025","unstructured":"Sun W, Wang S, Han J, Zhuo L, Cao J, Zhou F (2025) Symptoms of hematologic tumors patients after CAR-T therapy: a systematic review and meta-analysis. J Pain Symptom Manage 69(3):304\u2013317","journal-title":"J Pain Symptom Manage"},{"key":"6727_CR8","doi-asserted-by":"crossref","unstructured":"Sadowski K, Ploch W, Downar A, Giza W, Szczes D, Olejarz W et al (2025) Nephrotoxicity in CAR-T cell therapy. Transpl Cell Ther","DOI":"10.1016\/j.jtct.2025.03.007"},{"issue":"1","key":"6727_CR9","doi-asserted-by":"crossref","first-page":"103693","DOI":"10.1016\/j.htct.2024.06.008","volume":"47","author":"F Nunes","year":"2025","unstructured":"Nunes F, de Gusmao BM, Wiginesk FB, Manenti E, Soares J, Freitas MG et al (2025) From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy. Hematol Transfus Cell Ther 47(1):103693","journal-title":"Hematol Transfus Cell Ther"},{"issue":"2","key":"6727_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","volume":"27","author":"T Joseph","year":"2025","unstructured":"Joseph T, Sanchez J, Abbasi A, Zhang L, Sica RA, Duong TQ (2025) Cardiotoxic effects following CAR-T cell therapy: a literature review. Curr Oncol Rep 27(2):135\u2013147","journal-title":"Curr Oncol Rep"},{"key":"6727_CR11","doi-asserted-by":"crossref","unstructured":"Vichare A, Lee JS, Duong TQ (2025) Neuroimaging Findings of CAR T-Cell-Associated Neurotoxicity: A Review. Neurology: Clinical Practice. in press","DOI":"10.1212\/CPJ.0000000000200488"},{"issue":"11","key":"6727_CR12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1177\/08850666241253537","volume":"39","author":"D Kurtz","year":"2024","unstructured":"Kurtz D, Sharma A, Sharma A, Soubani AO (2024) Epidemiology and outcomes of hospitalized chimeric antigen receptor T-cell (CAR-T) therapy patients who developed acute respiratory failure. J Intensive Care Med 39(11):1146\u20131154","journal-title":"J Intensive Care Med"},{"issue":"7","key":"6727_CR13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cncr.33347","volume":"127","author":"AE Bencomo-Alvarez","year":"2021","unstructured":"Bencomo-Alvarez AE, Gonzalez MA, Rubio AJ, Olivas IM, Lara JJ, Padilla O et al (2021) Ethnic and border differences on blood cancer presentation and outcomes: a Texas population-based study. Cancer 127(7):1068\u20131079","journal-title":"Cancer"},{"issue":"23","key":"6727_CR14","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","volume":"11","author":"J Emole","year":"2022","unstructured":"Emole J, Lawal O, Lupak O, Dias A, Shune L, Yusuf K (2022) Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States. Cancer Med 11(23):4440\u20134448","journal-title":"Cancer Med"},{"issue":"7","key":"6727_CR15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","volume":"30","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Sun F, Teigland C, Kilgore KM, Mohammadi I, Chambers J et al (2024) Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers. Transplant Cell Ther 30(7):714\u2013725","journal-title":"Transplant Cell Ther"},{"key":"6727_CR16","doi-asserted-by":"crossref","first-page":"103821","DOI":"10.1016\/j.ebiom.2022.103821","volume":"76","author":"JQ Lu","year":"2022","unstructured":"Lu JQ, Lu JY, Wang W, Liu Y, Buczek A, Fleysher R et al (2022) Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19. EBioMedicine 76:103821","journal-title":"EBioMedicine"},{"issue":"10","key":"6727_CR17","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1161\/HYPERTENSIONAHA.123.21174","volume":"80","author":"V Zhang","year":"2023","unstructured":"Zhang V, Fisher M, Hou W, Zhang L, Duong TQ (2023) Incidence of new-onset hypertension post-COVID-19: comparison with influenza. Hypertension 80(10):2135\u20132148","journal-title":"Hypertension"},{"issue":"1","key":"6727_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s15010-021-01646-1","volume":"50","author":"JY Lu","year":"2022","unstructured":"Lu JY, Hou W, Duong TQ (2022) Longitudinal prediction of hospital-acquired acute kidney injury in COVID-19: a two-center study. Infection 50(1):109\u2013119","journal-title":"Infection"},{"issue":"1","key":"6727_CR19","doi-asserted-by":"crossref","first-page":"17972","DOI":"10.1038\/s41598-022-22741-9","volume":"12","author":"JY Lu","year":"2022","unstructured":"Lu JY, Ho SL, Buczek A, Fleysher R, Hou W, Chacko K et al (2022) Clinical predictors of recovery of COVID-19 associated-abnormal liver function test 2 months after hospital discharge. Sci Rep 12(1):17972","journal-title":"Sci Rep"},{"issue":"10","key":"6727_CR20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/ndt\/gfad020","volume":"38","author":"JY Lu","year":"2023","unstructured":"Lu JY, Boparai MS, Shi C, Henninger EM, Rangareddy M, Veeraraghavan S et al (2023) Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI. Nephrol Dial Transplant 38(10):2160\u20132169","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"6727_CR21","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1111\/dom.15120","volume":"25","author":"K Dell\u2019Aquila","year":"2023","unstructured":"Dell\u2019Aquila K, Lee J, Wang SH, Alamuri TT, Jennings R, Tang H et al (2023) Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: comparison with influenza and pre-pandemic data. Diabetes Obes Metab 25(9):2482\u20132494","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6727_CR22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ejh.14058","volume":"111","author":"A Feit","year":"2023","unstructured":"Feit A, Gordon M, Alamuri TT, Hou W, Mitchell WB, Manwani D et al (2023) Long-term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID-19: a 2.5-year follow-up study. Eur J Haematol 111(4):636\u2013643","journal-title":"Eur J Haematol"},{"key":"6727_CR23","doi-asserted-by":"crossref","unstructured":"Eligulashvili A, Darrell M, Miller C, Lee J, Congdon S, Lee JS et al (2022) COVID-19 patients in the COVID-19 recovery and engagement (CORE) clinics in the Bronx. Diagnostics (Basel) 13(1)","DOI":"10.3390\/diagnostics13010119"},{"issue":"4","key":"6727_CR24","doi-asserted-by":"crossref","first-page":"e15277","DOI":"10.1016\/j.heliyon.2023.e15277","volume":"9","author":"JY Lu","year":"2023","unstructured":"Lu JY, Buczek A, Fleysher R, Musheyev B, Henninger EM, Jabbery K et al (2023) Characteristics of COVID-19 patients with multiorgan injury across the pandemic in a large academic health system in the Bronx, new York. Heliyon 9(4):e15277","journal-title":"Heliyon"},{"key":"6727_CR25","first-page":"798897","volume":"8","author":"JY Lu","year":"2021","unstructured":"Lu JY, Buczek A, Fleysher R, Hoogenboom WS, Hou W, Rodriguez CJ et al (2021) Outcomes of hospitalized patients with COVID-19 with acute kidney injury and acute cardiac injury. Front Cardiovasc Med 8:798897","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"6727_CR26","doi-asserted-by":"crossref","first-page":"e1004263","DOI":"10.1371\/journal.pmed.1004263","volume":"21","author":"A Eligulashvili","year":"2024","unstructured":"Eligulashvili A, Gordon M, Lee JS, Lee J, Mehrotra-Varma S, Mehrotra-Varma J et al (2024) Long-term outcomes of hospitalized patients with SARS-CoV-2\/COVID-19 with and without neurological involvement: 3-year follow-up assessment. PLoS Med 21(4):e1004263","journal-title":"PLoS Med"},{"issue":"1","key":"6727_CR27","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1038\/s41598-024-58430-y","volume":"14","author":"A Eligulashvili","year":"2024","unstructured":"Eligulashvili A, Darrell M, Gordon M, Jerome W, Fiori KP, Congdon S et al (2024) Patients with unmet social needs are at higher risks of developing severe long COVID-19 symptoms and neuropsychiatric sequela. Sci Rep 14(1):7743","journal-title":"Sci Rep"},{"issue":"1","key":"6727_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO et al (2019) Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"1","key":"6727_CR29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18810","volume":"202","author":"A Kuhnl","year":"2023","unstructured":"Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A et al (2023) CAR T in patients with large B-cell lymphoma not fit for autologous transplant. Br J Haematol 202(1):65\u201373","journal-title":"Br J Haematol"},{"issue":"1","key":"6727_CR30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","volume":"27","author":"AS Kittai","year":"2021","unstructured":"Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L et al (2021) Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis. Transplant Cell Ther 27(1):46\u201352","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"6727_CR31","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/bloodadvances.2024013148","volume":"8","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Grover NS (2024) Race and insurance: real-world insights on CAR-T outcomes. Blood Adv 8(10):2589\u20132591","journal-title":"Blood Adv"},{"issue":"2","key":"6727_CR32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A et al (2023) Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 389(2):148\u2013157","journal-title":"N Engl J Med"},{"issue":"26","key":"6727_CR33","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood.2023023447","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB et al (2024) Real-world and clinical trial outcomes in large B-cell lymphoma with Axicabtagene Ciloleucel across race and ethnicity. Blood 143(26):2722\u20132734","journal-title":"Blood"},{"issue":"9","key":"6727_CR34","first-page":"581","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T et al (2022) Real-World evidence of Axicabtagene Ciloleucel for the treatment of large B cell lymphoma in the united States. Transpl Cell Ther 28(9):581. e1-e8","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"6727_CR35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O\u2019Donnell EK, Jacobson CA et al (2020) Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis 76(1):63\u201371","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"6727_CR36","first-page":"581","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T et al (2022) Real-World evidence of Axicabtagene Ciloleucel for the treatment of large B cell lymphoma in the united States. Transpl Cell Ther 28(9):581 e1- e8","journal-title":"Transpl Cell Ther"},{"key":"6727_CR37","doi-asserted-by":"crossref","first-page":"1435127","DOI":"10.3389\/fimmu.2024.1435127","volume":"15","author":"H Wan","year":"2024","unstructured":"Wan H, Weng S, Sheng S, Kuang Z, Wang Q, Hu L (2024) Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis. Front Immunol 15:1435127","journal-title":"Front Immunol"},{"issue":"9","key":"6727_CR38","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS et al (2024) A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 30(9):2667\u20132678","journal-title":"Nat Med"},{"issue":"30","key":"6727_CR39","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y et al (2024) Five-year follow-up of standard-of-care Axicabtagene Ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol 42(30):3581\u20133592","journal-title":"J Clin Oncol"},{"issue":"12","key":"6727_CR40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","volume":"19","author":"G Claps","year":"2022","unstructured":"Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S et al (2022) The multiple roles of LDH in cancer. Nat Rev Clin Oncol 19(12):749\u2013762","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"6727_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jtct.2025.01.001","volume":"31","author":"E Abadir","year":"2025","unstructured":"Abadir E, Wayte R, Li W, Gupta S, Yang S, Reaiche E et al (2025) Reduced chimeric antigen receptor T cell expansion postinfusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies. Transplant Cell Ther 31(3):159\u2013165","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"6727_CR42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8(8):958\u2013971","journal-title":"Cancer Discov"},{"issue":"1","key":"6727_CR43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB et al (2019) Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol 86(1):42\u201354","journal-title":"Ann Neurol"},{"issue":"12","key":"6727_CR44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32(12):1091\u20131101","journal-title":"CNS Drugs"},{"issue":"6","key":"6727_CR45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE et al (2022) Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther 28(6):294\u2013302","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"6727_CR46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","volume":"21","author":"J Rice","year":"2019","unstructured":"Rice J, Nagle S, Randall J, Hinson HE (2019) Chimeric antigen receptor T Cell-Related neurotoxicity: Mechanisms, clinical Presentation, and approach to treatment. Curr Treat Options Neurol 21(8):40","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"6727_CR47","doi-asserted-by":"crossref","first-page":"e1576","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H (2022) Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis 14(6):e1576","journal-title":"WIREs Mech Dis"},{"issue":"2","key":"6727_CR48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"6727_CR49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jir.2021.0057","volume":"41","author":"R Dong","year":"2021","unstructured":"Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C et al (2021) Prognostic significance of cytokine release syndrome in B cell hematological malignancies patients after chimeric antigen receptor T cell therapy. J Interferon Cytokine Res 41(12):469\u2013476","journal-title":"J Interferon Cytokine Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06727-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:14Z","timestamp":1767485714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06727-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6727"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06727-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Einstein-Montefiore Institutional Review Board with an exemption for informed consent and a HIPAA waiver (2024-16474).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}